On-going Expansion at Pharmaron's Liverpool Gene Therapy and Biologics CDMO Site
Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!
With the first phase in our new build project finished, this marks a significant step forward in our £151M, 800,000 sq ft investment to expand our development and commercial production capabilities—supported by the UK Government’s Life Sciences Innovation Manufacturing Fund. The expansion quadruples our process development and analytical capacity and includes 3,500 sqM of future GMP commercial-scale space.
This milestone reflects the incredible collaboration across our teams and partners, and our shared commitment to advancing gene therapy, biologics, and vaccine innovation in the UK. The expanded facility will enable us to better serve our domestic and international partners with their development and manufacture of vaccines and gene therapy drug development—bringing life-changing medicines to patients faster and at greater scale.
